Hypoglycemia is common in patients using insulin analog regimens, and even nonsevere hypoglycemia is associated with clinically significant effects on patient well-being and functioning, patient and physician management of glycemic targets, and overall health care utilization.22 The benefits of achieving tight glycemic control (e.g., lower glycemic targets) in patients with both type 1 and type 2 diabetes are well known but are counterbalanced by the ongoing risk of symptomatic hypoglycemia.9 Symptomatic hypoglycemia in patients with diabetes remains a persistently under addressed issue. This evidence concerns the gene INS and Hypoglycemia.